NCT Number: NCT00132457
Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection
The purpose of this study is to determine if, among women who were treated for a prior chlamydial infection, home-based, self-collected vaginal swabs can increase rescreening for chlamydia in comparison with rescreening in the clinic. The study design is two randomized trials with enrollment at multiple family planning clinics and sexually transmitted disease (STD) clinics following a common protocol.
Looking for future studies?
Notify MeKey information
Conditions
Age range
16 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
Primary location
Louisiana State University (LSU) Health Sciences Center, New Orleans, Louisiana, United States
About this study
The study consists of two complementary trials, denoted as Part A and Part B. In Part A, women/girls who had a positive test for chlamydia will be enrolled when they visit the study clinics for treatment. After written informed consent is obtained, women will be randomly assigned to the Clinic Group, in which they will be advised to return to the clinic for rescreening for chlamydia, or the Home Group, in which women will be asked to collect a vaginal swab at home and mail it to the study laboratory for chlamydia testing. In part B, women who were tested and empirically treated for a chlamydial infection will be called if their tests were positive. Enrollment will be offered over the phone after verbal consent. Rescreening will be scheduled 3 months after treatment of the initial infection for women in both trials.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Women/girls with a lab-confirmed genital chlamydia infection
Exclusion criteria
- Women who are pregnant, or are trying to conceive in the following 3 months.
- Women who are planning to move in the following 3 months or currently living outside the study areas.
- Inability to understand spoken English adequately to assure informed consent and compliance with study procedures.
- Self-reported HIV infection; other serious illnesses or disability.
- Self-reported allergy to macrolide antibiotics such as azithromycin.
- Referrals from providers or clinics other than the STD or family planning clinics, unless women are re-tested at the STD clinics and test positive for chlamydia.
Treatment and study plan
Primary outcomes
-
Percent of women rescreened for chlamydia
Sponsors and collaborators
Lead sponsor
Centers for Disease Control and Prevention
Fed
Registry information
Important dates
- Study start
- 2003
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- Aug 22, 2005
- Registry last updated
- Jan 7, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Immunopathogenesis of Chlamydia
NCT00607659
Adnexal Diseases, Bacterial Infections
Little Rock, Arkansas, United States
View Trial DetailsDoxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro
NCT07500415
Bacterial Infections, Bacterial Infections and Mycoses
Rio de Janeiro, Brazil
View Trial DetailsScreening of Gonococcal and Chlamydial Infections in the Third Trimester
NCT03073538
Bacterial Infections, Bacterial Infections and Mycoses
View Trial DetailsPartner Notification for Chlamydia in Primary Care
NCT00112255
Bacterial Infections, Bacterial Infections and Mycoses
Bristol, Avon, United Kingdom
View Trial Details